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ORIGINAL ARTICLE
Centrosomal kinase Nek2 cooperates with oncogenic pathways
to promote metastasis
TK Das1, D Dana2, SS Paroly2, SK Perumal3, S Singh4, H Jhun2, J Pendse1, RL Cagan1, TT Talele4 and S Kumar2
Centrosomal kinase Nek2 is overexpressed in different cancers, yet how it contributes toward tumorigenesis remains poorly
understood. dNek2 overexpression in a Drosophila melanogaster model led to upregulation of Drosophila Wnt ortholog wingless
(Wg), and alteration of cell migration markers—Rho1, Rac1 and E-cadherin (Ecad)—resulting in changes in cell shape and
tissue morphogenesis. dNek2 overexpression cooperated with receptor tyrosine kinase and mitogen-activated protein kinase
signaling to upregulate activated Akt, Diap1, Mmp1 and Wg protein to promote local invasion, distant seeding and metastasis. In
tumor cell injection assays, dNek2 cooperated with Ras and Src signaling to promote aggressive colonization of tumors into
different adult fly tissues. Inhibition of the PI3K pathway suppressed the cooperation of dNek2 with other growth pathways.
Consistent with our fly studies, overexpression of human Nek2 in A549 lung adenocarcinoma and HEK293T cells led to activation of
the Akt pathway and increase in b-catenin protein levels. Our computational approach identified a class of Nek2-inhibitory
compounds and a novel drug-like pharmacophore that reversed the Nek2 overexpression phenotypes in flies and human cells. Our
finding posits a novel role for Nek2 in promoting metastasis in addition to its currently defined role in promoting chromosomal
instability. It provides a rationale for the selective advantage of centrosome amplification in cancer.
Oncogenesis (2013) 2, e69; doi:10.1038/oncsis.2013.34; published online 9 September 2013
Subject Categories: Cell cycle and growth regulation
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INTRODUCTION
Centrosomal kinases are important regulators of cell division. They
control key processes such as centrosome cycle, kinetochore–
microtubule attachment, spindle checkpoint/assembly, chromo-
some condensation and cytokinesis. Uncontrolled activity of these
kinases can lead to spindle abnormalities, centrosome fragmenta-
tion, premature centriole splitting, cytokinesis defects, multi-
nucleation, supernumerary centrosomes and chromosome
segregation errors. These cellular phenotypes, referred to as
chromosomal instability (CIN), are frequently observed in trans-
formed cells indicating that overexpression of mitotic kinases
might drive tumor progression in vivo by promoting CIN.1,2 Yet a
clear notion of the mechanism by which these kinases contribute
to tumorigenesis remains elusive.
Never-In-Mitosis-A-related kinase 2 (Nek2) is a serine/threonine
kinase that has a critical role in mitosis during the cell division
process.3 Uncontrolled Nek2 activity can lead to CIN as well as
abnormal chromosome content—often 2–3 times the content of a
normal diploid cell.4 Expression of Nek2 is elevated (three to
fivefold) in different forms of cancer cell lines, including invasive
cancer cells.5 In xenograft studies, uptake of Nek2 siRNA into the
tumor significantly reduced tumor size, suggesting Nek2 inhibition
can counter tumor progression in vivo.6 These findings suggest
that Nek2 regulates tumor progression in vivo and that Nek2
inhibition could be useful for developing anti-cancer therapeutics.
But like the other centrosomal kinases, the role of Nek2 in tumor
progression remains unclear.
Modeling cancer in cell lines has not fully captured the
complex cellular behavior of this disease.7 Whole-animal mouse
cancer models have proven useful in understanding programs
of tumor progression, but have been too costly and time-
consuming to develop for an expansive study of large numbers
of cancer-related genes.8 Recently the fruit fly, Drosophila
melanogaster, has been used to identify novel cancer risk factors
indicating the enormous translational potential of flies for
modeling cancer.9–12
We have developed and characterized the first whole-animal
Nek2 overexpression model using Drosophila melanogaster. Over-
expression of the fly Nek2 ortholog (dNek2) in developing fly
tissues led to increased centrosome number. It also enhanced cell
migratory behavior leading to distant seeding of cells. Molecular
analysis revealed that Nek2 overexpression led to upregulation of
secreted Wg protein, deregulation of Ecad, Rho1, Rac1 and
activation of Akt, proteins that are intricately connected to the
process of cell survival and migration. Nek2 cooperated with
receptor tyrosine kinase (RTK), Ret, to enhance local invasion,
distant seeding of cells as well as to increase the levels of the
activated Akt protein. Nek2 also cooperated with intracellular
signaling molecules, activated Ras and Src, to increase Mmp1,
Diap1 and Wg protein levels and drive metastasis. Using a novel
tumor cell injection assay in flies, we established that Nek2-
overexpressing cells could cooperate with other oncogenic
pathways to aggressively colonize various tissues in the adult
fly. Genetic or pharmacological inhibition of the PI3K pathway
1Department of Developmental and Regenerative Biology, Mount Sinai School of Medicine, New York, NY, USA; 2Department of Chemistry and Biochemistry, Queens College and
the Graduate Center of the City University of New York, Queens, NY, USA; 3Department of Chemistry, The Pennsylvania State University, University Park, PA, USA and
4Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, USA. Correspondence: Professor S Kumar, Department of
Chemistry and Biochemistry, Queens College and the Graduate Center of The City University of New York, 65-30 Kissena Blvd, Queens, NY 11367-1597, USA.
E-mail: Sanjai.Kumar@qc.cuny.edu
Received 25 June 2013; revised 23 July 2013; accepted 29 July 2013
Citation: Oncogenesis (2013) 2, e69; doi:10.1038/oncsis.2013.34
& 2013 Macmillan Publishers Limited All rights reserved 2157-9024/13
www.nature.com/oncsis
suppressed the cooperation phenotypes with Ret as well as Ras
and Src signaling, indicating that PI3K is a key effector pathway
downstream of Nek2 driving tumorigenesis. Overexpression of
human Nek2 in human cell lines also deregulated similar signaling
pathways leading to stabilization of b-catenin protein levels and
reduced b-catenin at the membranes, phenotypes consistent with
a pro-invasive state.
Currently there is considerable effort in trying to identify potent
and non-toxic small molecule inhibitors that inhibit Nek2 function.
By proceeding from virtual screening, to in vitro testing, to using
our fly model, we rapidly identified drug-like compounds most
optimal for Nek2 inhibition in vivo.
Our studies have uncovered a novel role for Nek2 in promoting
tumorigenesis by regulating an axis of metastasis and cell survival.
We have also identified a new set of Nek2 inhibitors, and
delineated a novel inhibitory pharmacophore for Nek2 kinase. Our
studies continue to highlight the advantages of combining whole-
animal genetic studies with rational drug discovery to yield
compounds with optimal therapeutic index.13
RESULTS
Drosophila Nek2 overexpression model
We first established if studying the Drosophila Nek2 ortholog
would be likely to recapitulate the kinase function of human Nek2.
Primary sequence alignment analysis (BLAST) of human and
Drosophila Nek2 kinase domains revealed that they shared a high
degree of amino-acid sequence conservation (Figure 1a—70%
sequence similarity and 50% sequence identity of amino-acid
residues in the N-terminal kinase domain). As the Drosophila Nek2
crystal structure is unavailable, a homology model was generated
using human Nek2 (PDB ID: 2JAV) as a template.14 A striking
similarity between the fly and human protein structures is evident
at both secondary and tertiary structure level (Figure 1b),
including a high degree of conservation of the key active site
residues (Figure 1c). The fly ortholog possesses important motifs
present in most kinase family members—hinge loop, HRD
and DFG motifs.14 Key residues required for optimal activity of
human Nek2 were also retained in the fly ortholog: amino-acid
residues of the activation segment and the autophosphorylation
sites. In addition, residues in human Nek2 that can be changed
to increase or decrease kinase activity in vitro were also conserved
in the Drosophila ortholog.15 Thus, a high conservation of these
key features suggested that fly Nek2 likely retains the key physio-
logical functions of its human counterpart.
We therefore generated a Drosophila Nek2 overexpression
model that allowed us to target inducible expression of dNek2 to
specific tissues using the GAL4-UAS system.16 We generated a
C-terminal fusion with green fluorescent protein (GFP) (UASdNek2-
GFP) to allow us to monitor the subcellular localization of ectopic
Nek2.
dNek2 overexpression leads to increased levels of Wg and
activated Akt
To establish if overexpression of Drosophila Nek2 could recapitu-
late key features of human Nek2 function, we monitored the
status of centrosomes. Overexpression of dNek2 in the peripodial
cells of the developing wing epithelium (ptc4dNek2-GFP;
Figure 2a, centrosomal marker g-tubulin) led to an increase in
the number of centrosomes. While some dNek2-GFP-expressing
cells had the usual 1–2 centrosomes per cell, others showed an
increase to 3–5 per cell (Figure 2a, cells outlined in red). As
predicted, Nek2-GFP signal was enriched over the centrosomes
and in some other subcellular regions. Overexpression of
vertebrate hNek2 in cultured cells led to a similar increase in
centrosome numbers, indicating that our model phenocopied
features of human Nek2 overactivity.3
To uncover potentially novel roles for this kinase, we next
overexpressed dNek2 in other developing tissues. Overexpression
of dNek2 in the thorax led to incomplete closure of the notum,
abnormal patterning of the bristles and a severe defect in the
scutellum (pnr4Nek2GFP; Figure 2c, abnormal patterning of
notum hairs—asterisk and malformed scutellum—arrow). The
notum and scutellum arise from the fusion of tissues from the
proximo-dorsal portion of the two wing discs. Altered activity of
regulators of cytoskeletal dynamics and cell migration in the
notum/scutellum can lead to similar tissue defects, e.g., activation
of the Jun N-terminal kinase (Jnk) pathway.17 dNek2 over-
expression in the developing eye led to extensive mispatterning
and positioning of ommatidia leading to a ‘rough eye’ phenotype
in the adult (Figure 2e). dNek2 overexpression along the anterior-
posterior (A/P) boundary of the wing disc resulted in severe
disruption of adult wing vein pattern (ptc4Nek2-GFP; Figures 2f
and g). As Nek2-GFP overexpression does not result in caspase
activation in larval discs (data not shown), this altered adult wing
phenotype is not likely due to increased cell death. Morphogens
such as wingless (Wg) and decapentaplegic (Dpp) regulate the
patterning of the developing wing disc along its axes.18 Wg is
expressed strongly in the dorso-ventral boundary of the wing disc
and at the edge of the pouch region, but only very low levels are
detectable in other areas of the wing disc. dNek2 overexpression
led to a significant increase in Wg protein levels across the entire
wing disc, which accumulated at distance from the dNek2
expression domain (Figures 2h and i, asterisks, i0), indicating
dNek2 promoted secretion of Wg protein. dNek2 overexpression
also led to a significant alteration in size and shape of the entire
tissue indicating an effect on signaling pathways that drive tissue
morphogenesis (Figures 2j and k). In addition, levels of adherens
junction component Ecad, a protein that is frequently down-
regulated before cell invasion,19 was also reduced in Nek2-
overexpressing cells (Figures 2l and l0). To understand which
signaling pathways Nek2 kinase was upregulating, we next
performed western analysis on wing discs.
Immunoblot analysis of wing disc tissues overexpressing
dNek2 showed consistently higher levels of pAkt (7654Nek2GFP;
Figure 2m), which is another bonafide regulator of growth,
migration and survival20 and is consistent with the observed
increased in thickness of the wing disc (Figure 2k). Overexpression
of dNek2 also altered relative levels of Rho-GTPase family proteins
Rho1 and Rac1. Through their antagonistic activities, these
proteins are central to driving actin–tubulin dynamics and cell
migratory behavior.21 We observed a decrease in Rho1 levels
and an increase in Rac1 levels, suggesting a disruption in the
balance of cytoskeletal dynamics of normal epithelium. Finally,
overexpression of dNek2 also led to decrease in adherens junction
component Ecad, as we had observed in our immunofluorescence
experiments in Figure 2l.
These experiments established three novel findings: Nek2
overexpression leads to secretion of increased levels of Wg,
activation of Akt, and alteration in the levels of Rho1, Rac1 and
Ecad proteins. All of these can have a significant impact on tumor
progression.
dNek2 cooperates with RTK signaling to regulate invasion and
differentiation
We next investigated if Nek2 overexpression can cooperate with
other signals by coexpressing dNek2 with an oncogenic isoform of
the RTK Ret, dRetMEN2. This fly model recapitulates essential
features of RetMEN2 oncogenic signaling, and was used to identify
a novel program of invasion/metastasis in humans.10,22
Coexpression of dNek2 and dRetMEN2B in stripes of cells along
the anterior-posterior (A-P) wing-disc compartment boundary led
to migration of a large number of GFPþ cells into the adjacent
compartment (non-GFP) with normal cells (ptc4Nek2-GFP,
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RetMEN2B; Figures 3a, c and e). Expression of oncogenic Ret alone
enhanced proliferation but had little effect on migration, and very
few cells migrated away from A-P boundary (ptc4RetMEN2B;
Figures 3b–d). Combined dNek2 and dRetMEN2B expression also
resulted in extensive rearrangement of the cytoskeletal tubulin
network (Figure 3e; a-tubulin), whereas expression of oncogenic
Ret alone had minimal effect on the organization of this network
(Figure 3d). Together, these findings indicated that dNek2 and
dRetMEN2B signals cooperated to provoke dramatic alteration of
cytoskeletal organization and promote cell migration.
Next we tested if dNek2 and oncogenic Ret signaling also
synergized in very few, clonally propagating, groups of cells using
the eyeless-FLPase-MARCM system.23 In this method, clonal cells
expressing transgenes also express GFP. Control flies with clones of
only GFP-expressing cells had normal adult eyes with visible clones
of GFPþ cells interspersed with non-GFP cells (Figure 3f). Expression
of RetMEN2B resulted in compensatory proliferation and apoptosis
during development leading to very rough eyes with overgrown, but
fully differentiated tissue (Figure 3g, red pigmentation). Coexpression
of dNek2 and RetMEN2B led to a significantly larger population of
GFPþ cells in the larval eye discs (Figures 3i and j), indicating a
growth advantage with this combination. Large groups of GFPþ
cells were also seen in neighboring tissues such as the proboscis
(Figures 3h and h0, arrowheads). Interestingly, we noticed the
emergence of large GFPþ outgrowths that did not have
pigmentation (Figures 3h and h0, arrowheads), indicating these cells
were not differentiated. Loss of differentiation or maintenance of
cells in a naı̈ve, undifferentiated state is another feature of cancer
cells.19 We therefore looked at the expression of differentiation
markers at earlier developmental stages of the larvae. While
expression of RetMEN2B maintained strong expression of
differentiation marker protein Elav (elav) (Figure 3i), coexpression
of dNek2 and RetMEN2B led to strong reduction of elav both inside and
outside the GFPþ clones, suggesting differentiation of the cells was
being compromised (Figures 3j and j0; arrowheads). Reduction of
elav expression non-autonomously outside the GFPþ clones
suggested that Nek2 could affect tumor progression autonomously
(yellow arrowhead) as well as non-autonomously (white arrowhead),
perhaps via secreted ligands such as Wg.
dNek2 cooperates with oncogenic Ras and Src signaling to
promote survival and metastasis
We next tested if Nek2 could cooperate with other intracellular
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Figure 1. (a) Primary sequence alignments shows that N-terminal region of hNek2 and dNek2 share 70% amino-acid sequence similarity and
50% identity. Key functional residues of hNek2 are indicated in the legend below. A significant number of these key residues are conserved in
dNek2. (b) Ribbon diagram of the superimposed view of the homology model-generated Drosophila (red) and human (yellow, (PDB ID: 2JAV))
Nek2 kinase structures. A striking similarity is evident between the two at the secondary and tertiary structure levels. (c) A close view of key
active site residues of human (green) and Drosophila (violet) Nek2 kinase, depicted as sticks.
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common features in many cancers and the Cagan laboratory had
previously established a fly model where both these pathways are
activated.24 Simultaneous activation of Ras and Src pathways
using the eyeless-FLPase-MARCM system led to limited tissue
overgrowth in larval eye discs (Figure 4b; Csk / ; RasV12).
Coexpression of dNek2 along with activated Ras and Src led to
significant overgrowth of GFPþ tissue (Figure 4c; dNek2; Csk / ;
RasV12, arrows) as well as appearance of secondary tumors in the
body of the larvae (Figure 4c, asterisk). dNek2; Csk / ; RasV12
cells showed significantly higher levels of inhibitor of apoptosis
(Diap1), matrix metalloprotease (Mmp1), Wg, as well as cell cycle
regulator protein CycE, compared with Csk / ; RasV12 cells
(Figures 4d–k). Cooperative upregulation of these proteins
indicates that dNek2 enhanced the tumorigenic potential of
Csk / ; RasV12 cells. Upregulation of Wg protein could also
promote growth of neighboring tumor cells non-autonomously,
allowing dNek2-overexpressing cells to en-masse promote tumor-
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To address whether dNek2; Csk / ; RasV12 cells could colonize
differentiated tissues in the adult, we developed a new tumor cell
injection assay. Dissociated dNek2; Csk / ; RasV12 cells were injected
into the dorsal notum region of wild-type (WT) adult flies, and within
10 days of injection GFPþ cells could be seen in various parts of the
adult body (Figure 4l). Injection of dNek2 cells (Figure 4l) or Csk / ;
RasV12 cells (data not shown) did not result in detectable tumor
populations in other body parts similar to our findings in the larvae
(Figures 4a–c). This assay is akin to tail-vein injection protocol in mice
and allows for a large number of injections to be performed and
tumors to be analyzed, and is a significant improvement over current
















































Figure 3. (a, b) Coexpression of dNek2-GFP and RetMEN2B, ptc4dNek2-GFP, RetMEN2B, in the developing wing discs led to large number of
GFPþ cells migrating away (bracket) from the anterior-posterior boundary (arrow) (a, a0). Expression of RetMEN2B alone showed almost no cell
migration (b, b0). These effects were quantitated and represented in c showing proportion of wing discs with migration phenotypes. Number
of discs analyzed for each experiment, GFP¼ 45, RetMEN2B¼ 32, dNek2-GFP(þ )RetMEN2B¼ 36, dNek2-GFP¼ 23. (d, e) Coexpression of dNek2-
GFP and RetMEN2B in the wing discs like in a and b led to severe alteration of polymerized tubulin network (e, e0) detected with a-tubulin
antibody. Extensive migration of cells is shown in e0 0. Little effects is seen on the polymerized tubulin network in wing discs expressing only
RetMEN2B (d, d0) and consequently very little cell migration (d0 0). (f–h) eye-FLP-MARCM experiments: (f ) Control flies expressing only UAS-GFP
showed a mixture on GFPþ and non-GFP cells as would be expected from clonal propagation. (g) Expression of RetMEN2B led to very rough
eyes, which retained pigmentation. (h, h0) Coexpression of dNek2-GFP and RetMEN2B led to enhancement of the rough eyes, emergence of
undifferentiated GFPþ tissues without pigmentation (h and h0, arrowheads), and a large increase of GFPþ cells in tissues adjacent to the eye
(h, arrowheads). (i, j) eye-FLP-MARCM experiment (as in f–h) eye discs stained with cell differentiation marker elav at the third instar stage,
stained. Coexpression of dNek2-GFP and RetMEN2B (j, j0), compared to expression of RetMEN2B alone (i, i0), led to severe disruption of
differentiation of cells both autonomously (GFPþ, yellow arrowhead) as well as non-autonomously (white arrowhead).
Figure 2. (a) dNek2 overexpression leads to centrosome amplification. Overexpression of dNek2, ptc4dNek2-GFP, in peripodial cells of the
wing disc resulted in centrosome amplification. In a0, g-tubulin, a centrosomal marker, shows 1–2 centrosomes (arrows) in some dNek2-GFP-
expressing cells (white outline) and 3–5 centrosomes in other dNek2-expressing cells (red outline). In a, GFP signal distribution of dNek2-GFP,
some of which localizes strongly over centrosomes. (b, c) dNek overexpression in the thorax leads to notum and scutellum defects,
pnr4dNek2-GFP (c), compared with control (b). (d, e) dNek2 overexpression in the eye, gmr4dNek2-GFP, led to patterning defects in the eye
(e) leading to disruption of the normal ordered hexagonal array of ommatidia (d). (f, g) dNek overexpression in the anterior-posterior
boundary of the developing wing disc, ptc4dNek2-GFP, led to abnormal veination pattern of the adult wing (g) compared with control (f ).
Magnified view of boxed in (g) is showed in (g0). (h, i) Wg protein levels are increased in third instar larval wing discs overexpressing Nek2,
ptc4dNek2-GFP (i) compared with control (h). Asterisks in i0 indicates higher levels of secreted Wg signal away from the patched (GFPþ cells)
boundary compared to control h0. Images shown are confocal z-stack overlays encompassing the entire thickness of the disc. (j, k) A cross-
sectional view (y–z plane) across of z-stack overlay in h and i shows the enormous difference in tissue size and shape between normal (j) and
Nek2-overexpressing cells (k). a, apical; d, dorsal; v, ventral. (l, l0) A cross-sectional view (x–z plane) of wing discs where Nek2-overexpressing
cells (green) show reduced levels of Ecad protein at junctions. White line shows region of reduced Ecad levels (two examples shown). Some
Ecad is seen internally away from the apical region, either due to basal migration or due to some multilayering of cells. (m) Western analysis of
larval wing disc tissues with dNek2-GFP overexpression throughout the entire disc, 7654dNek2-GFP. Asterisks indicate markers that were
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Figure 4. (a–c) eye-FLP-MARCM experiments showing GFPþ tissues (close-up view in bottom panels a0, b0, c0) with the genotypes dNek2GFP
(a, a0), Csk / ; RasV12(b, b0) and dNek2GFP; Csk / ; RasV12 (c, c0). dNek2GFP; Csk / ; RasV12 larvae show a significant increase in primary
tumor mass (arrows in c and c0) as well as appearance of secondary tumors (asterisks in c) at a distance from the primary tumors. (d–k) eye-FLP-
MARCM experiments showing that dNek2GFP; Csk / ; RasV12 tissues upregulate Diap1 (e, e0), Mmp1 (g, g0), Wg (i, i0) and CycE (k, k0), in
comparison with Csk / ; RasV12 tissues (d, d0, f, f0, h, h0 , j, j0). Epifluorescence0 images were taken at equivalent settings for each channel.
(l) Tumor cell injection experiments. GFPþ eye-FLP-MARCM tissues obtained from third instar larvae were dissociated and injected into the
dorsal notum of w- adult flies. Injection of dNek2GFP cells (n¼ 200) or Csk / ; RasV12 cells (data not shown) did not lead to GFPþ cells
seeding into the host fly. But injection of dNek2GFP; Csk / ; RasV12 cells led to appearance of distinct GFPþ foci within 10 days of injection
(20 out of 180 injected flies showed seeding injected tumor cells). Site of injection is visible as a dark scar (arrow) and three examples are
shown with tumor foci in parts of the body away from the injection site (asterisks).
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Taken together, these findings suggested that dNek2 could cooperate
with oncogenic signaling pathways to promote survival, invasion, and
metastasis and help tumor cells colonize a wide range of tissue types.
Cooperativity between dNek2 and oncogenic pathways depends
on PI3K-Akt signaling
To understand the molecular mechanism underlying the cooperativity
between Nek2 and oncogenic signaling pathways, we monitored
intracellular signaling markers using western analysis. We found that
combined dNek2 and RetMEN2B expression throughout the wing disc
resulted in higher levels of pJnk and pErk activity, compared with WT
tissue (7654dNek2, RetMEN2B; Figure 5a). These markers are involved in
promoting cell migration, and presence of higher levels of these
proteins compared with WT tissue is consistent with our migration
phenotypes. Interestingly, the levels of activated Akt (pAkt) were much
higher with combined dNek2 and RetMEN2B compared with dNek2 or
RetMEN2B expression alone, suggesting that pAkt was being activated in
a combinatorial manner (Figure 5a, asterisk). Similar results were
observed for cooperative interaction between dNek2 and Ras plus Src
signaling. Levels of pAkt were upregulated in a combinatorial manner
and levels of pJnk, Rho1 and Rac1 were also at high levels in the triple
genetic combination (Figure 5b). One outcome of increased Akt
activity is the inhibition of GSK3b activity that leads to the stabilization
of b-catenin ortholog armadillo (Arm).26 Indeed dNek2 as well
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Figure 5. (a) Western blot analysis of wing disc tissues following coexpression of dNek2-GFP and RetMEN2B, 765d4Nek2-GFP, RetMEN2B. pJnk and
pErk are maintained at high levels in tissues coexpressing Nek2-GFP and RetMEN2B. pAkt is the only marker (asterisks) whose levels are
increased above pAkt levels from expression of dNek2 or RetMEN2B alone. (b) Western blot analysis of eye-disc tissues using the MARCM
method following coexpression of dNek2-GFP and dNek2-GFP, RasV12, Csk / . pAkt level is increased combinatorially (asterisk). pGSK3b and
armadillo levels are also high, with armadillo levels marginally higher in the triple combination (asterisk). Relative levels of proteins are
indicated in red below each blot. Asterisk indicates markers whose levels are upregulated combinatorially. (c) Expression of dNek2-GFP in the
developing eye, gmr4dNek2-GFP, led to appearance of GFPþ foci in other tissues. Shown here are examples of foci in the thorax and legs (left
panels). Coexpression of Nek2-GFP and RetMEN2B led to larger foci appearing in similar regions of fly, suggesting a more stable seeding process
(right panels) without overall increase in the number of distantly seeded tumors (see quantitation in d). (d) Distant seeding in gmr4dNek2-GFP
flies can be suppressed by genetic or pharmacological inhibition of components of the PI3K pathway. Scatter plot, where each dot represents
total number of GFPþ foci in one fly. Red line represents median. dNek2¼ 35, dNek2;Ret2B¼ 36, dNek2;Ret2B;PI3K /þ ;S6K /þ ¼ 15.5,
dNek2þ LY294002 (100 mM)¼ 11, dNek2þ Rapamycin (1mM)¼ 5, dNek2þMK2206 (20mM)¼ 8.5, dNek2þ BEZ235 (5mM)¼ 4. Indicated doses
represent final concentration of drug in food that developing larvae ate. Brackets and blue asterisks indicate P-valueso0.05 as determined by
two-tailed students t-test. (e, f ) dNek2GFP; Csk / ; RasV12 eye-FLP-MARCM tissues from larvae that were fed with Akt inhibitor MK2206 (20 mM)
led to inhibition of growth of primary tumors (f, f0 ) [bracketed area enlarged in f0 ] compared with untreated tissues (e, e0).
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of pGSK3b (inhibitory phosphorylation), and in the latter case
significant upregulation of Drosophila Arm (Figure 5b, asterisk). Thus,
cooperative activation of Akt by dNek2 leads to increased levels
of b-catenin ortholog armadillo, which is another potent oncogenic
signal.19
The PI3K-Akt pathway is a well-known regulator of growth, survival
and invasion/metastasis in vertebrate cancer as well as
in Drosophila.20,27 Therefore, enhanced activation of pAkt by
dNek2 could be the primary cause for the increased survival,
migration and metastasis phenotypes. To test the requirement of the
PI3K-Akt pathway in promoting Nek2-dependent cooperation, we
developed another quantitative assay of cell migration. Targeting
dNek2 expression to the eye, which has high levels of endogenous
RTK activity, (but not GFP alone; Figures 5c and d) resulted in a large
number of GFPþ spots appearing in other parts of the adult flies,
including the notum, wing and legs (gmr4dNek2-GFP;
Figures 5c and d), a phenomenon we call ‘distant seeding’. Nek2-
dependent distant seeding of cells was strongly suppressed by
knockdown of Drosophila tor (gmr4dNek2-GFP, torRNAi), indicating
the requirement of the Akt pathway for this process. Coexpression of
dNek2 and RetMEN2B resulted in larger groups of cells visible in distant
body parts (gmr4dNek2-GFP, RetMEN2B; Figure 5c), showing again
that cooperation between dNek2 and RetMEN2B promoted survival of
cells in the process of ‘distant seeding’. In this context, reducing PI3K
pathway activity by removing a genetic copy of PI3K as well as S6K
significantly reduced the distant seeding phenotype (gmr4dNek2-
GFP, RetMEN2B, PI3K /þ , S6K /þ ; Figure 5d). Moreover, when we
fed dNek2-overexpressing flies with drugs that inhibited signaling at
different points along the PI3K cascade—LY294002 (PI3K inhibitor),
Rapamycin (Tor inhibitor), MK2206 (Akt inhibitor), BEZ235 (dual PI3K/
Tor inhibitor)—we significantly suppressed distant seeding of cells
(Figure 5d). Finally, cooperation between Nek2 and Ras plus Src
signaling was also suppressed by inhibition of the PI3K pathway.
dNek2; Csk / ; RasV12 eyeless-FLPase-MARCM larvae fed with
MK2206 showed significantly smaller primary tumors and complete
absence of secondary tumors (Figures 5e and f). In summary, our
genetic interaction and inhibitor studies showed that the PI3K-Akt
pathway was a key mediator of cooperativity between dNek2 and
other oncogenic signaling pathways.
In silico identification of Nek2-inhibitory drug-like candidates
Suitable non-toxic small molecule inhibitors of human Nek2
(hNek2) remain commercially unavailable. A rational computational
approach was undertaken to first identify drug-like compounds from
a small library that could potentially inhibit human Nek2 kinase
in vitro. In analyzing the primary sequence and crystallographic
structures of Nek2, we noticed that there exists a uniquely
conserved helical motif (aT) in Nek2 immediately following the
DFG motif also present in EGFR and HER2 kinases.13 As this aT motif
has a dynamic role in kinase activation, we surmised that EGFR/HER2
inhibitors that interact with the aT motif might also inhibit the
activity of Nek2 kinase. While the sequence alignments of Nek2 (PDB
ID: 2JAV)14 with that of EGFR (PDB ID: 2JIV)28 and HER2 (PDB ID:
3PP0)29 revealed only 22% sequence identity (45% sequence
similarity) and 27% sequence identity (49% sequence similarity),
respectively, the tertiary folds were remarkably similar (Figure 6a and
Supplementary Figure S1). A comparative analysis of the crystal
structure of an ATP-site directed, Nek2-bound pyrroleindolinone
inhibitor and the in silico docked pyrroleindolinone complex of EGFR
and HER2 further revealed that a significant binding overlap existed
between the three complexes (455% similar inhibitor-active site
residue interactions; Figure 6b). Significant similarities of interactions
observed in all three inhibitor-bound complexes, along with
similarities in secondary structural elements, indicated that certain
existing EGFR/HER2 inhibitors might also inhibit Nek2 activity.
Before testing existing EGFR/HER2 inhibitors as potential Nek2
inhibitors in silico, we first validated our computational Glide
docking algorithm on previously reported Nek2 inhibitors
(Supplementary Table S1). After validating our computational
strategy, we assembled a set of 27 commercially available
preclinical and clinical stage EGFR/HER2 inhibitors and
investigated in silico for their potential to serve as Nek2
inhibitors. Using a stringent selection criteria based on both
the Glide scoring function and the visual inspection
(Supplementary Information), a set of seven EGFR/HER2
inhibitors were chosen for in vitro evaluation (Supplementary
Table S2). Among these, neratinib (Glidescore¼  7.93 kcal/mol)
was found to be the top scoring compound with desired
structural attributes, with pelitinib as the second best
(Glidescore¼  7.86 kcal/mol). Structural analysis of the mole-
cular interaction of neratinib within the active site of Nek2
revealed a number of important binding features (Figure 6c and
Supplementary Information). Interestingly, many of these inter-
actions are also exhibited by pelitinib bound to Nek2-active site
(data not shown).
EGFR/HER2 inhibitors inhibit human Nek2 activity in vitro
reversibly
After identifying seven EGFR/HER2 inhibitors as potential Nek2
inhibitors from our in silico screen, we tested their ability to
inhibit the recombinant human Nek2 at 10 mM concentration
using 32P-ATP-based assay (Supplementary Information). We
identified neratinib and pelitinib as our lead Nek2-inhibitory
compounds (428% hit rate; Figure 6d). A comparison of these
two compounds revealed that they both contained a bicyclic,
6,7-disubstituted-4-(arylamino)quinoline-3-carbonitrile motif.
Slightly reduced activity of pelitinib as compared with neratinib
might be due to lack of 4-pyridylmethoxy substituent, which is
involved in hydrophobic interactions with the key a-T helix
residues, Gly161, Leu162 and Ala163. Interestingly, other known
EGFR/HER2 inhibitors such as afatinib, canertinib and gefitinib,
containing a bicyclic N-(3-chloro-4-fluorophenyl)quinazolin-4-
amine moiety, did not display any inhibition even at 20 mM. The
poor activity of these three inhibitors against Nek2 may be
explained based on the nature of substituent at the 7-position of
the quinazoline ring. For example, these structures carry either
very small methoxy group or very bulky oxolanyloxy and
morpholinylpropoxy substituent at this position instead of the
optimal ethoxy group. Similarly, mono and disubstituted N-
(aryl)quinazolin-4-amine containing EGFR inhibitors, erlotinib and
lapatinib, were not inhibitory under these conditions. Bulky
methoxypropoxy substituent at 7-position in case of erlotinib
and the absence of any group at 7-position in case of lapatinib
may be responsible for this dramatic loss of activity. It should be
noted here that both neratinib and pelitinib are known covalent
and irreversible inhibitors of EGFR and HER2. A dose–response
analysis revealed that neratinib and pelitinib displayed a
remarkable potency, and inhibited hNek2 with IC-50 values of
247 nM and 661 nM, respectively (Figure 6e). No time-dependent
inhibition was observed even on prolonged incubation (30 min)
of neratinib and pelitinib with hNek2. This indicated that despite
the presence of electrophilic crotonamide functionality, the
mode of hNek2 inhibition by these compounds was non-covalent
and reversible in nature. This is not surprising as Cys797 of EGFR
and the corresponding Cys805 of HER2 to which neratinib
establishes covalent bond is replaced by the Asp93 of Nek2
(Figure 6b).
Subset of EGFR/HER2 inhibitors inhibit dNek2 function in whole-
animal assays
Next we tested the ability of neratinib and pelitinib to effectively
inhibit dNek2 function in vivo using our fly overexpression model.
When increasing doses of these two drugs were fed to developing
larvae, the adult distant seeding phenotype was strongly
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suppressed. Quantitation of the number of total GFPþ foci with
one dNek2-GFP transgenic line showed a decrease in the
median number of foci from B37/animal (untreated) to B10/
animal (pelitinib) and B15/animal (Neratinib) after inhibitor
treatment. Similar suppression of ‘distant seeding’ was observed
with a second dNek2-GFP transgenic line (gmr4dNek2-GFP;
Figure 6f). Interestingly lapatinib, which had showed modest
inhibition of Nek2 in vitro had no effect on the distant seeding
phenotype (Figure 6f). Thus, our whole-animal model success-
fully discriminated between compounds that inhibited
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Figure 6. (a) Superimposition of Nek2 (PDB ID: 2JAV), EGFR (PDB ID: 2JIV) and HER2 (PDB ID: 3PP0) kinases. Nek2, EGFR and HER2 are shown as
yellow, orange and green colored ribbon models, respectively. Key conserved residues are also shown as stick model with color scheme by
element type as implemented in Maestro. (b) An analysis of the residues present within 5Å distance from the bound pyrroleindolinone
inhibitor in the co-crystal structure of hNek2 (PDB ID: 2JAV), and the corresponding residues at the equivalent positions from the in silico
docked complex of EGFR and HER2 kinases. A total of 26 residues are compared; red color, identical residues; pink color, similar residues; black
color, no homology; *Met86; Thr86 in wild type; Nek2/EGFR: 12 identical, 3 similar, 11 with no homology; Nek2/HER2: 11 identical, 3 similar,
12 with no homology. (c) Binding model of neratinib within the active site of human Nek2 kinase (left). Important amino acids are depicted as
sticks with the atoms colored as carbon—green, hydrogen—white, nitrogen—blue, oxygen—red, sulfur—yellow. Neratinib is shown as ball
and stick model with the same color scheme as above except carbon atoms are represented in orange and chloro atom as green. Anilino ring
centroid is displayed as green sphere. Dotted black line indicates hydrogen bonding interaction, whereas dotted red line indicates possible
hydrogen bonding and ionic interactions with distances in Å. (d) Inhibitory screening profile of selected small molecule library compounds
against wild-type (wt) human Nek2 kinase. The screening was performed at 10 mM inhibitory concentrations. (e) Dose–response curves for
neratinib- (red circle) and pelitinib-mediated (green square) inhibition of wt human Nek2 kinase. The points are experimental and the line
joining them is the fit to obtain the IC-50 values for neratinib as 247 nM and pelitinib as 661 nM, respectively. (f ) Nek2-driven cell migratory
phenotype (distant seeding; foci in GFP alone compared with Nek2GFP flies fed with DMSO) is suppressed upon treatment with pelitinib in
two transgenic fly lines (#1 and #6) and upon treatment with neratinib in one fly line (#1). Distant seeding quantitation was performed as in
Figure 5. Asterisks indicate P-values o0.05, in a two-tailed students t-test.
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Human Nek2 activates Akt and b-catenin pathways and can be
inhibited by compounds identified in Drosophila
We next investigated whether our findings on Drosophila Nek2
function translated to human cells. We overexpressed human Nek2
(hNek2) in A549 lung adenocarcinoma cell lines, which has been
shown to express high levels of K-Ras.30 A549 cells also have low levels
of endogenous Nek2 making this an ideal cell type to test the
consequences of hNek2 overexpression (Figure 7b). Transient over-
expression of hNek2 in A549 cells led to activation of the Akt pathway
(increase in pAkt and pS6), phosphorylation of GSK3b, stabilization of
b-catenin, as well as activation of pJNK and deregulation of Rac1
levels, all of which had parallels to our Drosophila studies (Figures 7a
and b). Interestingly, hNek2 overexpression in A549 cells led to a
severe reduction of b-catenin signal at the cell–cell adherens junction
complexes and increase of b-catenin signal in and around the nucleus
(Figure 7a). Reduced b-catenin in the adherens junction and its
translocation to the nucleus is indicative of invasive state of cells, thus
further supporting our hypothesis that Nek2 regulates invasion/
metastasis. hNek2 overexpression in non-cancerous HEK293T cells led
to deregulation of pAkt, pS6, pGSK3b, b-catenin, RhoA, pJNK, levels
indicating that these pathways are activated by Nek2 even in non-
tumorigenic human cells (Figure 7c). Finally, we tested whether
inhibiting hNek2 and the Akt pathway with the compounds we
identified in flies would suppress signaling initiated by hNek2. Indeed
both pelitinib and MK2206 suppressed hNek2-dependent increase
in cytosolic b-catenin and pJNK, and also partially restored the
deregulation of RhoA and pS6 levels (Figure 7d).
Together these results demonstrate that potent non-toxic Nek2
inhibitors can be identified using our whole-animal fly assay and
that these compounds can inhibit Nek2 activity in human cells.
Importantly, the fact that pelitinib, although less effective in vitro
in inhibiting hNek2 kinase activity, was more effective in inhibiting
the distant seeding phenomenon in vivo further reinforces the
need to include in vivo models in early drug discovery efforts. On
the basis of our studies, we propose that a novel Nek2-targeting
anti-cancer agent with low cellular toxicity can be developed
based on the bicyclic, 6,7-disubstituted-4-(arylamino)quinoline-3-
carbonitrile motif we have identified in our studies (Figure 8b).
DISCUSSION
Current thinking is that Nek2, like other centrosomal kinases,
could promote cancer progression by enhancing various mitotic
abnormalities that lead to CIN.31 Nek2 has not been implicated in
early stages of cancer progression, for example, by promoting
proliferation, survival and invasion. It is postulated that CIN is a




































































































































Figure 7. (a) Transient transfection of hNek2 in A549 cells led to upregulation of Akt pathway marker pS6, and strong deregulation of
b-catenin levels. In mock-transfected cells b-catenin is at the cell–cell junctions but hNek2-transfected cells show strong reduction of b-catenin
from the junctions. Note that some Nek2-transfected cells (asterisk) show increased b-catenin in and around the nucleus. (b) Western analysis of
transiently transfected hNek2 in A549 cells shows upregulation of pAkt, pS6, pGSK3b, b-catenin, pJNK and Rac1 levels. Deregulated proteins
indicated with asterisk. Constitutively active RET, hRETM918T, which is known to activate these pathways (pErk, pJNK, pAkt) is used as control. 40
(c) Western analysis of transiently transfected hNek2 in HEK293T cells shows upregulation of pAkt, pS6, pGSK3b, b-catenin, pJNK and
downregulation of RhoA. Relative levels of proteins between control and hNek2 overexpressing cells are indicated in red. (d) Nek2-dependent
upregulation of b-catenin and pJNK, in HEK293T cells can be inhibited by addition of pelitinib or Akt inhibitor MK2206. Inhibitors were added at a
concentration of 0.5mM for 2 h, following 24h of growth and transfection of cells.
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mutations with source of genetic variation through which to
promote tumorigenesis.
We show, for the first time, that Nek2 overexpression in
combination with oncogenic signaling pathways can promote
invasion and metastasis through combinatorial activation of the
Akt pathway, stabilization of b-catenin, upregulation of Wnt/Wg,
inhibition of apoptosis and deregulation of the Rho1-Rac1 balance.
As activation of the Akt, b-catenin and Wnt pathways can promote
growth, survival as well invasion, acquisition of increased Nek2
activity in tumors could also promote early stage cancer
progression. Invasion is the first step toward eventual metastasis,
the cause of most cancer-related deaths. During the process of
submission of our manuscript, one study showed that human Nek2
can activate the Akt pathway to promote drug resistance in
myeloma, once again supporting our conclusions.32 Our findings
implicate Nek2 in a novel and important role in the process of
tumor progression, that is, metastasis (Figure 8c; model), indicating
why Nek2 is frequently overexpressed in many cancers.
Overactive RTK as well as Ras and Src signaling is common to a
number of cancer types, for example in the lung (EGFR), breast
(HER2), thyroid (RET), pancreas (EGFR).33 Therefore, the potential
for Nek2 to synergize with other oncogenic signaling pathways,
like we have shown in Drosophila, and drive progression of a wide
range of cancers is enormous. Our own survey of the Oncomine
data set shows that Nek2 mRNA is indeed overexpressed in a
number of cancer types (Figure 8a). In the future, it would be
useful to analyze these data sets to ascertain if Nek2 levels
progressively increase as tumors become more invasive and
metastatic. Our studies show that indeed hNek2 overexpression in
human lung cancer cells can activate the same pathways that we
identified in our fly studies.
Our findings on Nek2 have a remarkable parallel to that of
another centrosomal kinase Aurora-A. Recent evidence suggests
that Aurora-A overexpression also induces Akt activation.34 Taken
together, these findings strongly suggest that centrosomal
kinases, for example, Nek2 and Aurora-A, can also activate the
Akt pathway and promote survival and/or invasion/migration and
metastasis during cancer progression. This posits a novel role for
centrosomal kinases beyond the conventional CIN. The notion that
deregulation of proteins that control the integrity of proper
nuclear division promote tumorigenesis only through CIN has
recently been challenged. Loss of spindle assembly checkpoint
components resulted in basal delamination of epithelial cells and
invasion in Drosophila,35 thus further supporting our findings that
cellular components previously thought to promote cancer
through CIN could also promote invasion and metastasis. It
might also provide an explanation as to why centrosomes are
frequently amplified in many cancers.
Our studies also make important predictions about how to
strategically inhibit cancers with Nek2 overexpression (Figure 8c). We
suppressed the ability of dNek2 to cooperate with other oncogenic
signaling axes through inhibition of the PI3K pathway. PI3K pathway
inhibitors, either singly or in combination, could be an effective
treatment for patients with high levels of Nek2. Another key finding
from our studies is that certain EGFR/HER2 inhibitors can inhibit Nek2
activity. This postulates a provocative notion that clinical success of
some of the EGFR/HER2 inhibitors could actually arise from inhibition




















































































Potency and Specificity Elements
Figure 8. (a) Analysis of Oncomine data showed that median hNek2 mRNA levels were consistently upregulated in patient tumors in the
following cancers—breast,41 pancreas,42 colorectal,43 lymphoma,44 esophagus,45 liver,46 bladder,47 lung,48 and cervical.49 (b) The chemical
structure of Nek2 pharmacophore identified for possible SAR studies. (c) Model showing how Nek2 signaling can promote metastasis by
cooperating with mitogen-activated protein kinase (MAPK) and RTK signaling; chromosomal instability (CIN). The PI3K-Akt pathway is an axis
through which Nek2 cooperates with other pathways, indicated by heavy black arrow. Akt pathway upregulation would inhibit GSK3b leading
to stabilization of b-catenin and increase in Wnt signaling. Wingless/Wnt itself is also upregulated by Nek2 expression, creating the possibility
of a complex feedback loop through interaction with other signaling pathways such as the Hippo cascade.50 Red inhibitory signs indicate
points along the signaling cascade where we can pharmacologically inhibit Nek2-driven tumorigenesis more effectively.
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Cancer cell lines where EGFR and Nek2 are both overactive should
respond better to dual Nek2/EGFR inhibitors such as pelitinib and
neratinib, compared with EGFR-specific inhibitors such as gefitinib
and erlotinib. Our studies also reveal that novel drug-like Nek2-
inhibitory pharmacophore with in vivo activity can be identified
using our developed Nek2 fly model. Our work lays the framework
for future studies that can further dissect the role of Nek2 in cancer
progression as well as develop more effective strategies to inhibit
the cancer-promoting Nek2 pathway.
MATERIALS AND METHODS
Generation of dNek2-GFP model, fly stocks and genetics
The gene encoding the D. melanogaster Nek2 kinase was PCR amplified from
a cDNA and was inserted into the NotI and XhoI restriction sites of
the pUAST vector containing a C-terminal GFP tag to obtain in vivo fluorescent
Nek2 proteins for intracellular imaging experiments. The identity of clones was
verified by dideoxy sequencing. dNek2-GFP-pUAST DNA was microinjected into
Drosophila embryos using standard techniques (BestGene Inc., Chino Hills, CA,
USA). The following fly stocks were used: UAS-RetMEN2B,10 and FRT 82B Csknull /
þ ; UAS RasV12. For the eyeless-FLP MARCM experiments, y,w,eyFLP1;
Act5C4yþ4Gal4, UAS-GFP; P[FRT]82B tub-Gal80 female virgins were crossed
to P[FRT]82B UASdRetMEN2B or P[FRT]82B UASdRetMEN2B; UASdNek2-GFP, or
P[FRT]82B Csknull /þ ; UASRasV12, and UASdNek2-GFP; P[FRT]82B Csknull /þ ,
UASRasV12 males and their progeny were raised in regular food. All flies were
raised at 25 1C using standard fly genetics.
Histology and antibodies
Third instar wing discs were staged and fixed in 4% paraformaldehyde.
Immunofluorescence was performed as described.36 Antibodies used were:
b-catenin, Rac1 (BD Biosciences, San Jose, CA, USA); pRet, pJnk, pAkt, pS6,
pGSK3b (Cell Signaling, Danvers, MA, USA); pSrc(Y418) (Invitrogen, Grand
Island, NY, USA); pERK, GFP (Sigma, St Louis, MO, USA); Arm, Ecad, Rho1,
a-tubulin, Syntaxin, Mmp1, Wg, CycE (Developmental Studies Hybridoma
Bank, Iowa City, IA, USA); gamma-tubulin, RhoA (Santa Cruz Biotechnology,
Santa Cruz, CA, USA); and anti-DIAP1 (from H. Steller).
Quantitation of GFP foci in dNek2-GFP flies and live imaging of
adult eyes
dNek2-GFP flies (lines #1 and #6) were crossed to GMR-Gal4 flies and placed
in vials containing different concentrations of the drugs, lapatinib,
pelatinib and neratinib, LY294002, Rapamycin, BEZ235, MK2206 or DMSO
(control). F1 progeny from the above crosses were scored for GFP-positive
eye phenotype and photographed using Leica M165FC fluorescence
stereoscope (Leica, Buffalo Grove, IL, USA). GFP-positive flies were further
analyzed for GFP foci in distant locations in the body, such as the wings,
legs, head and whole body. The GFP foci were quantitated and compared
in the drug-treated versus untreated control flies. The results were graphed
and subjected to statistical analysis using the PRISM-Graphpad Software.
Progeny of the eyeless-FLP MARCM experiments were imaged in a similar
manner with combined bright-light and fluorescence settings.
Tissue culture studies
The gene encoding WT human Nek2 was PCR amplified from a pGEM
plasmid containing the Nek2 gene and cloned into pCMV vector. A549 and
HEK293T cells were grown in RPMI1640 and DMEM media, respectively,
supplemented with 10% FBS and penicillin-streptomycin mix. Cells were
transfected with lipofectamine and cell lysis performed 24 and 48 h after
transfection. For imaging studies, cells were grown to 50% confluency in
Lab-TekII 8-chamber slides (Fisher, Pittsburgh, PA, USA), transfected and
grown for further 24 h in serum-free media.
Tumor cell injection into adult flies
Third instar larval eyeless-FLP MARCM eye discs (GFPþ ) of the indicated
genotype were dissected in 1 PBS on ice and dissociated in a solution
of artificial hemolymph37 (10 eye discs per fixed volume) in a 1.7-ml
eppendorf tube using a small plastic pestle. Dissociated tissue solution was
loaded onto a fine tipped needle and approximately equal
volumes were injected into the dorsal region of the notum of an adult
fly using a microinjector. Flies were allowed to recover and placed in fly
food vials and monitored for GFP expression every couple of days. The
tumor cell injection assay is an adaptation from a cell injection assay
developed by Tzou et al.38
Western blot analysis
Ten third instar discs of each genotype were dissolved in lysis buffer (50 mM
Tris, 150 mM NaCl, 1% TritonX-100, 1 mM EDTA) supplemented with protease
inhibitor cocktail (Sigma) and phosphatase inhibitor cocktail (Sigma). Total
protein in each sample was quantitated using Bio-Rad protein assay (Bio-Rad
Laboratories, Hercules, CA, USA). Samples were boiled, resolved on SDS–PAGE
and transferred by standard protocols. Membranes were stripped with Sigma
Restore stripping buffer and reprobed with other antibodies to assess signal
under exactly the same loading conditions.
Computational analysis
For obtaining a three-dimentional structure of Drosophila Nek2 kinase,
homology modeling was performed using the Prime software (Schrödinger
Inc., New York, NY, USA) with human Nek2 (PDB: 2JAV) as a template. For
docking studies, the initial protein structure of Nek2 along with crystal-
lographic water molecules was refined by means of default parameters
mentioned in protein preparation tool implemented in Maestro v9.0 and
Impact program v5.5. The protonation states of residues were adjusted to
the dominant ionic forms at pH 7.4. Refined protein was further used to
generate a grid by selecting bound inhibitor pyrroleindolinone. The grid
thus generated was further used for docking of a focused library of EGFR/
HER2 kinase inhibitors at the active site of Nek2. Commercially available
small molecule drug library comprising of 27 clinically investigated EGFR/
HER2 inhibitors (Selleck Chemicals, Houston, TX, USA and LC Laboratory,
Woburn, MA, USA) were built using the fragment dictionary of Maestro
v9.0 and energy minimized by Macromodel program v9.7 (Schrödinger
Inc.) using the OPLSAA force field with the steepest descent followed by
truncated Newton conjugate gradient protocol. The low-energy 3D
structures of all compounds were generated by LigPrep v2.3: different
protonation states at physiological pH ±2, all possible tautomers and ring
conformations. In a similar manner, 10 known Nek2 inhibitors were also
processed for the validation of our docking strategy. The output of
Ligprep run comprising of a total of 37 compounds was used as input for
docking experiments. Docking of a set of 27 EGFR/HER2 inhibitors and 10
known Nek2 inhibitors within the active site of Nek2 was performed using
the ‘Extra Precision’ (XP) mode of Glide docking program v5.5 and
the default parameters. All computations were carried out on a Dell
Precision 47n dual processor with the Linux OS (Red Hat Enterprise WS,
Raleigh, NC, USA).
Acquisition of recombinant human Nek2 kinase, in vitro screening
and IC-50 determination
The gene encoding WT Nek2 was PCR amplified from a pGEM plasmid
containing the Nek2 gene. C-terminally (His)6-tagged Nek2 enzyme was
achieved by incorporating the Nek2 gene into pET32a. The WT lambda
protein phosphatase (LPP2) open reading frame was PCR amplified from
the lambda genomic DNA and inserted into the pET22b expression
vector. Nek2 and LPP2 –pET22b vectors were co-transformed into BL21
(RIPL) codon plus E. coli cells and expressed under isopropyl-b-D-
thiogalactoside induction, as described earlier.14 Overexpressed
proteins were purified to homogeneity by a metal-affinity Ni-NTA
column followed by SP-sepharose column and evaluated for
appropriate activity (Supplementary Figures S2 and S3). All in vitro
Nek2 kinase assays were performed in triplicates at 25 1C at pH 7.5 in a
kinase assay buffer (50 mM Tris HCl, 2 mM dithiothreitol, 0.3 mg/ml bovine
serum albumin, 0.5 mM Na2EDTA) using wild-type human Nek2 enzyme.
For in vitro enzyme assay, a peptide-based Nek2 substrate, Ac-IRRLSTRRR-
CONH2,
39 was synthesized by standard Fmoc-chemistry and used
(Supplementary Information). See Supplementary Information for deter-
mination of IC-50 values.
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